

Comparative Outcomes of the Molteno3[®] S-Series and Baerveldt[®] Glaucoma Implants

Dixon MW, Moulin TA, Margolis MS, et al. Comparative Outcomes of the Molteno3 and Baerveldt Glaucoma Implants. *Ophthalmol Glaucoma*. 2020;3(1):40-50. doi:10.1016/j.ogla.2019.10.003

STUDY OVERVIEW

Retrospective chart review to investigate whether the Molteno3[®] S-Series is noninferior to the Baerveldt[®]

117 patients (117 eyes):

Molteno3[®] SS-185 / SL-245 (40 eyes)

Baerveldt[®] BG-101-350 / BG-103-250 (77 eyes)



Molteno3[®] SL-245



Molteno3[®] SS-185



Baerveldt[®] BG-101-350



Baerveldt[®] BG-103-250

SURGICAL TIME

Molteno3[®] versus Baerveldt[®] 350mm²

Surgical time for Molteno3[®] S-Series was 15.7 minutes shorter ($P < 0.001$)

Molteno3[®] versus Baerveldt[®] 250mm²

Surgical time for Molteno3[®] S-Series was 4.3 minutes shorter ($P = 0.32$).



-15.7
MINUTES

Molteno3[®] S-Series versus Baerveldt[®] BG-101-350



-4.3
MINUTES

Molteno3[®] S-Series versus Baerveldt[®] BG-103-250

OUTCOME MEASURES

	Molteno3 [®] (S-Series)	Baerveldt [®] (101-350, 103-250)
Baseline Mean IOP	22.8 ± 8.1 mmHg	23.6 ± 7.2 mmHg
Postop Mean IOP	16.6 mmHg ($p = 0.0203$)	17.0 mmHg
Baseline Medications (n)	3.3 ± 0.8	3.4 ± 1.0
Postop Medications (n)	2.0 ± 1.43	2.1 ± 1.41

© 2020, Nova Eye Medical Ltd. E&OE. Patents pending and/or granted.

Molteno® and Molteno3® are trademarks of Nova Eye Medical Ltd. Baerveldt® is a trademark of Johnson & Johnson, Inc.

INDICATIONS: The Molteno3® is indicated to reduce intraocular pressure in neovascular glaucoma and glaucoma where medical and conventional surgical treatments have not been successful, to control the progression of disease.

CONTRAINDICATIONS: Patients with the following conditions may not be suitable candidates for the Molteno3®: 1. intraocular infection, 2. rheumatoid arthritis, scleritis and immune corneal melt syndromes, 3. Scleral Buckle.

COMPLICATIONS: Possible complications with the use of the Molteno3® include, but are not limited to: choroidal detachment, retinal detachment, expulsive haemorrhage, pupillary block, lenticulo-ciliary block, shallowing and flattening of the anterior chamber, intraocular infection, diplopia, loss of central vision, hypotony and corneal endothelial damage.

ADVERSE EVENTS: Possible adverse events with the use of the Molteno3® include, but are not limited to: corneal endothelial damage when the tube touches the corneal endothelium, breakdown of the tissues overlying the bleb, diplopia when the placement of the implant interferes with the action of the extraocular muscles, corneal decompensation, progression of lens opacities, cystoid macular oedema, retinal detachment and intraocular infection

PRECAUTIONS: Caution should be taken with supra-Tenon implantation; erosion of the conjunctiva is known to result from the raised edge of the oval pressure ridge (Molteno3® G-Series) of surgical techniques, proper use of the surgical instruments, and post-operative patient management are considerations essential to a successful outcome.

